In clinical samples, single-cell RNA sequencing and untargeted metabolomics have shown that the inhibition of receptor tyrosine kinase (RTK) and mevalonate pathways via MK-2206 and MK-803 impairs energy metabolism in EGFR-activated GBM [133,134]. This evidence concerns the gene EGFR and glioblastoma.